Skip to main content

Table 1 The characteristics of the pooled studies

From: Prognostic value of microRNA-21 in pancreatic ductal adenocarcinoma: a meta-analysis

Study Year Country Ethnicity Sample size Stage Results Survival analysis HR (95 % CI) for prognostic outcomes Adjuvant chemotherapy
Dillhoff 2008 USA Caucasian 80 NR OS KM OS, 4.08 (1.98, 8.38), P = 0.037 NR
Giovannetti a 2010 Italy Caucasian 28 I–III OS, DFS U OS, 3.1 (1.4–7.3), P = 0.008 Y
DFS, 4.4 (1.8–10.7), P = 0.001
Giovannetti b 2010 Italy Caucasian 31 IV OS, PFS U OS, 3.1 (1.4–7.1), P = 0.01 Y
PFS, 2.4 (1.1–5.3), P = 0.03
Hwang 2010 Korea Asian 82 II–IV OS, DFS M OS, 2.26 (1.34, 3.80), P = 0.002 Y
DFS, 2.793 (1.466–5.319), P = 0.002
Jamieson 2012 UK Caucasian 48 II–IV OS M OS, 3.22 (1.21–8.58), P = 0.019 Y
Liu 2012 China Asian 38 I–IV OS KM OS, 2.89 (1.22–6.81), P = 0.02 NR
Nagao 2012 Japan Asian 65 I–IV OS U OS, 2.32 (1.19–4.52), P = 0.045 NR
Wang 2013 China Asian 177 III–IV OS M OS, 1.71 (1.15–2.54), P = 0.008 Y
Kadera 2013 USA Caucasian 145 I–IV OS U OS, 1.1 (0.7–1.6), P = 0.7 NR
Papaconstantinou 2013 Greece Caucasian 88 I–IV OS M OS, 1.72 (1.25–12.3), P = 0.019 NR
Ma 2013 China Asian 78 I–IV OS M OS, 2.60 (1.15–5.87), P = 0.021 NR
Dhayat 2015 Germany Caucasian 91 II OS, RFS M OS, 3.06 (1.37–6.85), P = 0.0064 Y
RFS, 2.25 (1.06–4.77), P = 0.0338
Khan 2015 UK Caucasian 12 IV OS, PFS KM OS, 1.46 (0.41–5.21), P = 0.564 Y
PFS, 4.7 (1.1–19.7), P = 0.032
  1. OS overall survival, DFS disease-free survival, RFS relapse-free survival, PFS progression-free survival, KM Kaplan–Meier analysis, U univariate analysis, M multivariate analysis, Y yes, NR not reported